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Abbreviations 
OS oxidative stress, ROS reactive oxygen species, CRC Colorectal cancer,  ET electron transfer, ΔGdesolv,CDS free energy of water desolvation,  
ΔGlipo,CDS lipophilicity free energy, CDS cavity dispersion solvent structure of the first solvation shell, HOMO highest occupied molecular orbital, 
LUMO lowest unoccupied molecular orbital , R2multiple correlation coefficient, the F test of significance, SEE standards errors for the estimate, 
standard errors of the variables SE(ΔGdesolCDS), SE(ΔGlipoCDS), SE(Dipole Moment), SE (Molecular Volume), LD50 drug toxicity, ID90 drug 
concentration that produces 90% inhibition of cell growth 
 
Abstract 
It has been found that a free radical mechanism is involved in the cytotoxicity of most of a panel 
of 12 anti-colorectal cancer drugs tested against a panel of 9 colorectal cancer variants. The 
colorectal cancers Ht-29, LoVo and WiDr do not appear to involve free radical oxidative stress 
processes, although such processes may be too small to be detected or are kinetically slower than 
cell membrane or other drug-target interactions. 
The colorectal cancer variants 320, OM-1, 205 and SW-620 CRC show the strongest 
dependencies on free radical processes. 
The toxicity LD50 of the tested anti-colorectal cancer drugs is linearly related to the HOMO-
LUMO energy gap, and can be a useful theoretical screening tool for designing anti-colorectal 
cancer drugs. 
 
Introduction 
Colorectal cancer (CRC) or bowel or colon cancer develops in the bowel or rectum. It is the 
fourth most common cause of cancer death after lung, stomach, and liver cancer and is more 
common in developed countries with highest rates in Australia, New Zealand, Europe and the 
US. 
Chemotherapy is usually offered for stage 3 and 4 CRC, including the use of capecitabine, 
fluorouracil, uracil, irinotecan, oxaliplatin. Some specific regimens used for CRC are CAPOX, 
FOLFOX, FOLFOXIRI. Antiangiogenic drugs such as bevacizumab can also be used in first line 
therapy.[1,2] 
The role of redox processes in the development of CRC is well known. The role of reactive 
oxygen species (ROS) in the redox modification of lipids, proteins, DNA is involved in many 
biological processes related to diseases including CRC. ROS also play an important role in 
cellular signaling. The spread of lipid peroxidation from malignant into the adjacent non-
malignant colon tissue also occurs. A low catalase activity is indicative of oxidative-
antioxidative disorders. Oxidative stress is an imbalance between ROS production and the ability 
of naturally occurring biological antioxidants. ROS include free radicals such as the superoxide 
anion (O2•−), hydroxyl radical (HO•) and the non-radical molecules such as hydrogen peroxide 
(H2O2), and singlet oxygen. The primary source of ROS is the mitochondria. ROS can invoke 
single and double strand DNA breaks, and the common genetic mutations include p53, KRAS, 
APC, and BRAF mutations. [3-7] Intracolonic production of ROS notably HO• has been 
physically observed.[8] 
Because CRC has higher incidence rates in western countries, sporadic human CRC could be 
linked to various environmental and lifestyle factors, such as dietary habits, obesity, and physical 
inactivity. While there is much evidence of a link between ROS induced oxidative stress and 
carcinogenesis, there is some debate whether oxidative stress is a cause or consequence of CRC. 
[6] A comprehensive study of 81 primary CRCs in clinical stages II, III, and IV has shown that 
the progression of CRC is associated with enhanced oxidative stress and the gradual 
advancement of oxidative-antioxidative disorders is followed by progression of CRC. [7] 
 
Cancer cells characteristically have a high antioxidant capacity that regulates ROS to levels that 
are compatible with cellular biological functions but still higher than in normal cells. Targeting 
these high antioxidant defence mechanisms is a strategy to kill cancer cells but not normal cells. 
[9-12] However, all antineoplastic agents generate some ROS as they induce apoptosis in cancer 
cells, because one of the pathways of drug-induced apoptosis involves the release of cytochrome 
C from mitochondria. When this occurs, electrons are diverted from the electron transfer system 
to oxygen by NADH dehydrogenase and reduced coenzyme Q10, resulting in the formation of 
superoxide radicals. [9] 
  
There is extensive evidence supporting involvement of electron transfer (ET), reactive oxygen 
species (ROS) and oxidative stress (OS) in the mechanism of many anticancer drugs. These free 
radical ET agents function catalytically in redox cycling with formation of ROS from oxygen. 
[13-15] The metabolism of a drug may generate a reactive intermediate that can reduce 
molecular oxygen directly to generate ROS. [16]  
We have recently shown that the radical form of a wide range of current antineoplastic drugs is 
involved in oxidative stress processes in human DLD-1 human colorectal cancer cells as 
determined by the CellROX assay. The oxidative stress capability of these drugs is dependent on 
the lipophilicity and electron affinity of the drugs in water. All of the drugs examined are known 
to be involved in oxidative processes to some degree according to literature sources. The 
antioxidant properties of the radical drug species in the ORAC or ORAC/Cu assays are also 
dependent on the lipophilicity and electron affinity properties of the drugs. Linear equations have 
been derived which can predict the oxidative stress in colorectal cancer cells and the redox 
behavior in the ORAC assays. [17] 
Study objectives 
Determine (a) whether the efficacy of a panel of anticancer drugs previously tested against a 
panel of CRCs can be ascribed to free radical chemotherapy and its effect on oxidative stress, 
and (b) if so develop a drug efficacy screening methodology using quantum mechanically 
derived molecular properties of the drugs  
Results 
Scheithauer [18] has previously used a panel of 12 anti-CRC drugs to examine their efficacy (the 
ratio of the concentration required to decrease cell growth to 10% of the control to 0.1 of the 
peak plasma concentration in humans, ie ID90:0.1 peak plasma concentration) against 9 variants 
of CRC. Drugs were tested for 1 hour exposure as well as continuous exposure using standard 
clinical patient treatment formulations. Cell lines were propagated as monolayer cultures. 
Animal toxicology LD50 for the 12 drugs was also determined. A reasonable correlation (P < 
0.02) between the percentage of in vitro response rate of the entire panel of cell lines for the 1 
hour incubation and the known in vivo response data for the various drugs was observed (using a 
cut-off definition of in vitro drug efficacy of less than 30 for the ID90:0.1 peak plasma 
concentration). 
 
We have previously described a model that has been shown to apply to a wide range of drug 
transport, binding, metabolic and cytotoxicity properties of cells and tumours (Equation 1).  
The model is based on establishing linear free energy relationships between the four drug 
properties and various biological processes. Equation 1 has been previously applied to passive 
and facilitated diffusion of a wide range of drugs crossing the blood brain barrier, the active 
competitive transport of tyrosine kinase inhibitors by the hOCT3, OATP1A2 and OCT1 
transporters, and cyclin-dependent kinase inhibitors and HIV-1 protease inhibitors.   The model 
also applies to PARP inhibitors, the anti-bacterial and anti-malarial properties of 
fluoroquinolones, and active organic anion transporter drug membrane transport, and some 
competitive statin-CYP enzyme binding processes. There is strong independent evidence from 
the literature that ΔGdesolvation, ΔGlipophilicity, the dipole moment and molecular volume are good 
inherent indicators of the transport or binding ability of drugs. [19-30]  
Equation 1: 
Transport or Binding or Cytotoxicity = ΔGdesolv,CDS + ΔGlipo,CDS + Dipole Moment + 
Molecular Volume or  Electron Affinity 
Or 
Transport or Binding or Cytotoxicity = ΔGdesolv,CDS + ΔGlipo,CDS + Dipole Moment + 
Electron Affinity 
Eq 1 uses the free energy of water desolvation (ΔGdesolv,CDS) and the lipophilicity free energy 
(ΔGlipo,CDS) where CDS represents the non-electrostatic first solvation shell solvent properties. 
CDS may be a better approximation of the cybotactic environment around the drug approaching 
or within the protein receptor pocket, or the cell membrane surface or the surface of a drug 
transporter, than the bulk water environment outside the receptor pocket or cell membrane 
surface. The CDS includes dispersion, cavitation, and covalent components of hydrogen 
bonding, hydrophobic effects. Desolvation of water from the drug (ΔGdesolv,CDS) before binding 
in the receptor pocket is required, and hydrophobic interactions between the drug and protein 
(ΔGlipo,CDS) is a positive contribution to binding. ΔGlipo,CDS is calculated from the solvation 
energy in n-octane. In some biological processes, where biological reduction may be occurring, 
and the influence of molecular volume is small, the reduction potential (electron affinity) has 
been included in place of the molecular volume. In other processes, the influence of some of the 
independent variables is small and can be eliminated to focus on the major determinants of 
biological activity.  
We have recently used this model to develop a predictive model of the transport and efficacy of 
hypoxia specific cytotoxic analogues of tirapazmine and the effect on the extravascular 
penetration of tirapazamine into tumours. [19]  It was found that the multiparameter model of the 
diffusion, antiproliferative assays IC50 and aerobic and hypoxic clonogenic assays for a wide 
range of neutral and radical anion forms of tirapazamine (TPZ) analogues showed: (a) 
extravascular diffusion is governed by the desolvation, lipophilicity, dipole moment and 
molecular volume, similar to passive and facilitated permeation through the blood brain barrier 
and other cellular membranes, (b) hypoxic assay properties of the TPZ analogues showed 
dependencies on the electron affinity, as well as lipophilicity and dipole moment and 
desolvation, similar to other biological processes involving permeation of cellular membranes, 
including nuclear membranes, (c) aerobic assay properties were dependent on the almost 
exclusively on the electron affinity, consistent with electron transfer involving free radicals being 
the dominant species.  
The model has also been recently applied to triple negative breast and ovarian cancers where 
transient and stable free radicals are involved in the cytotoxic oxidative stress processes. The 
electron affinity of the various drugs, along with the water desolvation, lipophilicity and dipole 
moment,  has been shown to be an important predictor of cytotoxic efficacy. [28-30] 
In our recent study of ORAC and CellROX free radical anticancer drugs and oxidative stress in 
colorectal cancer cells [17] we found that eq 2 was applicable. 
Eq 2. 
Oxidative Stress or Oxidative Properties = ΔGdesolv,CDS + ΔGlipo,CDS + Dipole Moment + 
Electron Affinity 
Screening methodology 
Given the successful anti-tumorigenic model as described by eq 1 and 2 for wide range of 
anticancer drugs, the screening model used was to calculate five molecular parameters for the 
panel of 12 anti-CRC drugs from Scheithauer [18]: (1) the free energy of water desolvation 
(ΔGdesolv,CDS), (2) the lipophilicity free energy (ΔGlipo,CDS), (3) the dipole moment in water, (4) 
the molecular volume in water, and (5) the adiabatic electron affinity, AEA, (or reduction 
potential) in water. These values are shown in Table 1 along with the anti-tumour efficacy 
(ID90:0.1 peak plasma concentration) against the 9 CRC tumours for the 1 hour exposure as well 
as continuous exposures. 
Stepwise multiple regression was then applied to seek out which drug molecular properties 
(Table 1) had the largest effect on the CRC variants shown in Table 1(a) for the 1 hour exposures 
and Table 1(b) for the continuous exposures. These results are shown in Table 2(a) and 2(b) 
which shows the molecular properties which had significant impacts on the CRC variants for 1 
hour and continuous exposures respectively.  
The statistical significance of the linear regression equations in Table 2(a) and 2(b) are shown (F 
test) and which relationships showed major statistical outliers, particularly BCNU and 
Vincristine, to which a number of CRC variants were resistant. The 1 hour exposures 
(approximating a bolus injection of drugs) are possibly more informative than the continuous 
exposures (approximating intravenous injection) since processes whereby drugs have to first 
permeate the cell membrane, then interact with the appropriate cystolic target is confounded 
when continuous exposure regimes are used. We have previously shown that desolvation, 
lipophilicity, molecular volume and dipole moment all play roles in both cell membrane 
permeation and drug-target interaction in cytotoxic processes.  
The molecular properties in Table 1 have been scaled as indicated to provide a direct comparison 
of the linear regression coefficients to allow a direct relative comparison of the absolute 
magnitude of which molecular properties are most significant.  
The findings from Table 2(a) and (b) are: 
(1) CRC variants 320, OM-1, 205 and SW-620 CRC show the greatest effect on AEA for both 1 
hour and continuous exposures.  
(2) Ht-29, LoVo and WiDr do not show any significant dependency on AEA for 1 hour and 
continuous exposures. It is known that WiDR is a derivative of the colon adenocarcinoma 
cell line Ht-29. [31]  
(3) Variants 205, DLD-1 and HOT-3 show only minor partial dependencies on AEA but major 
dependencies on desolvation, lipophilicities or molecular volumes of the drugs for 1 hour 
exposures. 
(4) Where there is no effect of drug AEA on the CRC variants, there are dependencies on drug 
desolvation, lipophilicity, molecular volume or dipole moment for both exposure regimes.  
Table 3 shows the relationship between animal toxicology of the panel of drugs and the HOMO-
LUMO gap for the drugs. The linear relationship is LD50 =  14273.2 (HOMO-LUMO) -1805.2 
(R2 0.416, SEE 907.3, SE(HOMO-LUMO) 5346, F 7.13, Significance 0.023. No other linear 
dependencies were separately observed with desolvation, lipophilicity, molecular volume, dipole 
moment or AEA. 
Discussion 
Scheithauer [18] found that the response rate for the panel of drugs for 1 hour exposure was 
similar to in vivo clinical data. This study finds a strong or partial dependency on AEA for 5 of 
the 9 drugs for 1 hour exposure. Similar findings were found for continuous exposure, but SW-
620 showed dependency on AEA but not for the 1 hour exposure. Overall only Ht-29, LoVo and 
WiDr showed no dependency on AEA, indicating possibly that a different non-oxidative stress 
mechanism occurs when treated by the panel of drugs, or kinetic effects related to cell membrane 
permeability or cell target interaction are dynamically dominating over free radical processes. 
Scheithauer [18] found that 320DM, OM-1 and Ht-29 closely resembled in vivo clinical results. 
This study finds that 320DM and OM-1 cytotoxicities are strongly dependent on AEA for both 1 
hour and continuous exposure.  
These results are consistent with our previous study where it was shown that the radical form of 
a wide range of current antineoplastic drugs is involved in oxidative stress processes in human 
DLD-1 human colorectal cancer cells as determined by the CellROX assay. The oxidative stress 
and redox capability of these drugs was dependent on the lipophilicity and electron affinity of the 
drugs in water. [17]  
Scheithauer [18] found a good correlation between the peak plasma level in humans and the 
LD50 values in normal (non-tumor-bearing) mice (P < 0.01), indicating that LD50 is  useful for 
screening investigational drugs for their activity in colorectal cancer. However we have recently 
shown that LD50 of a series of Pt(II)- and Pt(IV)-nitroxide conjugate drug treatments of healthy 
and leukemic mice is inversely linearly related to the HOMO-LUMO energy gap of the drugs. 
Also in another series of common neutral Pt(II) and Pt(IV) drugs, we also found that the LD10 
was directly related to the HOMO-LUMO gap, unlike the Pt-Nitroxides, which are stable free 
radicals, and which showed a negative LD50 relationship with the HOMO-LUMO gap, consistent 
with antioxidant behaviour having a positive lowering effect on lethality. [32]   
This study also demonstrates that the LD50 of the panel of 12 anti-CRC drugs is quite strongly 
linearly related to the HOMO–LUMO gap, indicating that the HOMO-LUMO gap can be a 
useful theoretical screening tool for designing anti-CRC drugs. 
Conclusions 
It has been found that a free radical mechanism is involved in the cytotoxicity of most of a panel 
of 12 anti-colorectal cancer drugs tested against a panel of 9 colorectal cancer variants. The 
colorectal cancers Ht-29, LoVo and WiDr do not appear to involve free radical oxidative stress 
processes, although such processes may be too small to be detected or are kinetically slower than 
cell membrane or other drug-target interactions. 
The colorectal cancer variants 320, OM-1, 205 and SW-620 CRC show the strongest 
dependencies on free radical processes. 
The toxicity LD50 of the tested anti-colorectal cancer drugs is linearly related to the HOMO-
LUMO energy gap, and can be a useful theoretical screening tool for designing anti-colorectal 
cancer drugs. 
Experimental 
All calculations were carried out using the Gaussian 09 package. Energy optimizations were at 
the DFT/B3LYP/6-31G(d,p) (6d, 7f) or DFT/B3LYP/3-21G (for larger molecules) level of 
theory for all atoms. Selected optimizations at the DFT/B3LYP/6-311+G(d,p) (6d, 7f) level of 
theory gave very similar results to those at the lower level. Optimized structures were checked to 
ensure energy minima were located, with no negative frequencies. Energy calculations were 
conducted at the DFT/B3LYP/6-31G(d,p) (6d, 7f) for neutral compounds and DFT/B3LYP/6-
31+G(d) (6d, 7f) level of theory for anions with optimized geometries in water, using the 
IEFPCM/SMD solvent model. With the 6-31G* basis set, the SMD model achieves mean 
unsigned errors of 0.6 - 1.0 kcal/mol in the solvation free energies of tested neutrals and mean 
unsigned errors of 4 kcal/mol on average for ions. [33] The 6-31G** basis set has been used to 
calculate absolute free energies of solvation and compare these data with experimental results for 
more than 500 neutral and charged compounds. The calculated values were in good agreement 
with experimental results across a wide range of compounds. [34,35] Adding diffuse functions to 
the 6-31G* basis set (ie 6-31+G**) had no significant effect on the solvation energies with a 
difference of less than 1% observed in solvents, which is within the literature error range for the 
IEFPCM/SMD solvent model. HOMO and LUMO calculations included both delocalized and 
localized orbitals (NBO). 
 
Electron affinities (EA) in eV in water were calculated by the SCF difference between the 
optimised/relaxed neutral and optimised radical species method as previously described. [19,28-
30] It has been shown that the B3LYP functional gives accurate electron affinities when tested 
against a large range of molecules, atoms, ions and radicals with an absolute maximum error of 
0.2 eV. [36-38]  
 
It is noted that high computational accuracy for each species in different environments is not the 
focus of this study, but comparative differences between various species is the aim of the study. 
The literature values for drug efficacy and toxicity used in the stepwise multiple regressions have 
much higher experimental uncertainties than the calculated molecular properties. The statistical 
analyses include the multiple correlation coefficient R2, the F test of significance, standards 
errors for the estimates (SEE) and each of the variables SE(ΔGdesolCDS), SE(ΔGlipoCDS), SE(Dipole 
Moment), SE (EA) as calculated from “t” distribution statistics. Residual analysis was used to 
identify outliers.  
 
 
 
Table 1  Molecular properties of anti-CRC drugs 
ΔGdesolv,CDS 
Water kcal/mol 
ΔGlipo,CDS 
kcal/mol 
Dipole 
Moment 
Water D 
Molecular 
Volume/20 
Water  
cm3/mol 
5.AEA 
Water eV 
BCNU -4.84 -4.44 4.28 6.25 16.2 
Bisantrene 2.4 -13.56 11.04 13.3 14.9 
Cis-Platinum vert -4.57 -0.47 17.08 5.2 9.1 
Doxorubicin -11.11 -9.69 9.35 19.9 17.3 
5-Fluorouracil -5.76 -2.87 6.62 4 11.45 
FUDR -7.12 -5.07 6 8.4 11.5 
Melphalan vert -5.66 -6.41 10.7 10.25 4.55 
Methotrexate -6.11 -11.81 3.47 16.4 13.85 
Mitomycin C -4.54 -3.64 9.9 10.55 18.05 
MitoxantroneH+H+ -12.54 -10.87 16.23 16.45 36.3 
PALA -11.17 -4.09 9.91 6.85 10.3 
Vincristine -15.04 7.65 18.5 32.55 7.65 
Footnotes: BCNU: l,3-bis(2-chloroethyl)-1-nitrosourea; FUDR: 5-fluoro-2-deoxyuridine; PALA: N-(phosphonacetyl)-L-aspartate; Cis-
Platinum and Malphalan given as vertical electron affinity as adiabatic electron affinities showed elongation of Pt-Cl and CH2-Cl bonds, 
MitoxantroneH+H+ is di-protonated at physiological pH. Molecular volumes divided by 20, AEAs multiplied by 5 
 
 
Table 1(a) Drug efficacy ID90:0.1 peak plasma concentration  
1 Hour Exposure 320DM OM1 Ht29 205 DLD1 HOT3 LoVo WiDr SW620 
BCNU 146.2 840.2 588.5 289.3 275.7 1094.7 632.8 232.7 132.6 
Bisantrene 59.8 16.7 6.1 6.1 8.7 19.9 7.8 7.9 20.5 
CisPt vert 42.1 54.5 48.3 61 25.5 82.4 41.3 30.5 20.6 
Doxorubicin 227.8 120 90.3 126.5 6.5 307.8 8.8 6.5 193.7 
5-FU 10 11 5.6 18.3 5.4 24.6 1.4 1.3 30.1 
FUDR 64.1 9.5 1.2 30.6 32.1 29.5 8.1 12.7 50.9 
Melphalan vert 28.1 21.3 25.5 144.2 28.4 82.3 28.7 17.8 47.3 
Methotrexate 26.1 47.7 37.5 24.8 21.4 251.4 450.6 6.2 102.2 
Mitomycin C 81.2 52.7 6.7 80.5 16.1 393.8 8.7 49.5 9.3 
MitoxantroneH+H+ 165.2 90.8 32 118 36.2 321.6 6.4 50.6 10 
PALA 234.8 76.3 246.9 444.2 318.8 53 112.8 385.6 44.9 
Vincristine 25.37 1045 517 912 616 9999 719 6 1019 
Footnote: from ref 18 
 
 
Table 1(b)  Drug efficacy ID90:0.1 peak plasma concentration  
Continuous 
Exposure 320DM OM1 Ht29 205 DLD1 HOT3 LoVo WiDr SW620 
BCNU 91.5 290 330.5 120.6 108.6 335.1 62.4 203.8 91.7 
Bisantrene 5.8 7.3 0.4 0.4 3.3 75.6 0.4 0.3 0.4 
CisPt vert 0.9 7.2 36.2 14.5 7.2 484.8 6.9 5.6 76.9 
Doxorubicin 7 158 124.7 10 7.3 1083.7 6.5 4.8 6.5 
5-FU 0.6 1.7 5.2 1.2 0.3 39.9 1.1 4.6 1.5 
FUDR 0.9 5.2 35.4 1.2 5.7 12 2.8 1.2 15.6 
Melphalan vert 19.2 10 36.3 35.5 34.9 405.5 7.3 9.5 287 
Methotrexate 0.9 33 18.2 16.6 163.5 140.7 134.6 0.3 2432.8 
Mitomycin C 3.5 0.9 42 5.4 0.1 140.5 0.1 2.6 0.1 
MitoxantroneH+H+ 4 114 78.4 6.4 18.8 924.4 0.1 3.4 5.4 
PALA 11.1 0.5 221 7.1 19 33 29.8 146.6 139 
Vincristine 1412 2011 10 10 408 2935 8 75 9971 
Footnote: from ref 18 
 
Table 2(a) Major dependencies of drug efficacies on molecular properties 1 hour exposures 
Colorectal 
Cancer Cell 
Line 
Tumour Origin & 
Cell Differentiation 
Antineoplastic 
Effect: 1 Hour 
Exposure 
Ratio 
relative to 
AEA 
Significance 
F Test 
Statistical 
Outliers 
(Resistance)  
320DM Primary Moderate AEA 0.148 
OM-1 Metastatic Well AEA 0.127 
Ht-29 Primary Well Lipo+DM+Vol 0.06 excl BCNU 
205 Ascites Poor Desolv+AEA <-40:-12>* 0.023 excl BCNU 
DLD-1 Primary Poor Desolv+AEA <-12:-4> 0.307 
excl BCNU, 
Vincristine 
HOT-3 Metastratic Well Lipo+Vol+AEA <-39:33:7>** 0.015 
excl BCNU, 
Vincristine 
LoVo Lymph Node Well Lipo+DM+Vol 0.081 
WiDr Primary Moderate Desolv+Vol 0.187 
SW-620 
Lymph Node 
Moderate Lipo+DM+Vol 0 
Footnote: * Regression coefficients desolvation:AEA ratio is -40:-12 indicating that desolvation effect is greater than Adiabatic 
Electron Affinity effect by 40/12 times; ** lipophilic free energy:molecular volume:AEA coefficients in ratios 39:33:7 
 
 
Table 2(b)  Major dependencies of drug efficacies on molecular properties continuous 
exposures 
Colorectal 
Cancer 
Cell Line 
Tumour Origin & 
Cell Differentiation 
Antineoplastic 
Effect: Continuous 
Exposure 
Significance 
F Test 
Statistical 
Outliers 
(Resistance)  
320DM Primary Moderate AEA 0.054 
excl BCNU, 
Vincristine 
OM-1 Metastatic Well AEA 0.393 excl BCNU 
Ht-29 Primary Well Desolv 0.155 excl BCNU 
205 Ascites Poor AEA 0.254 excl BCNU 
DLD-1 Primary Poor Lipo+DM+Vol 0.002 
HOT-3 Metastratic Well Lipo+DM+Vol 0 
LoVo Lymph Node Well Lipo+DM 0.096 
WiDr Primary Moderate Lipo+DM 0.341 
SW-620 
Lymph Node 
Moderate AEA 0.103 
exclude 
Methotrexate, 
Vincristine 
 
Table 3  Drug toxicology 
LD50 
HOMO -
LUMO 
Gap 
mg/kg eV 
BCNU 42 4.930814 
Bisantrene 245 2.87903 
CisPt vert 26.8 4.968911 
Doxorubicin 24 2.824606 
5-FU 171 5.3526 
Melphalan vert 29.6 5.194771 
Methotrexate 69 3.494021 
Mitomycin C 12 2.824606 
MitoxantroneH+H+ 86.5 2.566092 
Vincristine 5.8 3.951182 
FUDR 550 5.32811 
PALA 4000 7.015254 
Footnote: LD50 values from ref 18 
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